RxDoctor Payments DataLook up a doctor →

Christine Hatch

Primary Care · Newburyport, MANPI 1831304138

Payments from drug & device makers

$11,407in general payments, 2019–2025

Across 693 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lundbeck LLC$665
  • AstraZeneca$621
  • Novo Nordisk$594
  • GSK$589
  • Lilly USA, LLC$535
  • plus $6K from 51 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie212$2,670
Lundbeck LLC34$665
AstraZeneca35$621
Novo Nordisk37$594
GSK39$589
Lilly USA, LLC28$535
Pfizer32$496
Astellas Pharma US Inc16$421
Boehringer Ingelheim19$395
Takeda Pharmaceuticals U.S.A., Inc.16$388
Corium, LLC25$374
Johnson & Johnson25$343
Novartis21$334
Amgen(2 entities)18$302
Sumitomo Pharma America, Inc.11$294
Otsuka America Pharmaceutical, Inc.11$218
Sunovion Pharmaceuticals Inc.9$207
E.r. Squibb & Sons, L.L.C.10$198
Idorsia Pharmaceuticals US Inc11$153
Abbott6$110
Exact Sciences4$104
Merck5$101
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$86
Teva Pharmaceuticals USA, Inc.4$78
Axsome Therapeutics, Inc.4$78
Shield Therapeutics Inc4$74
Esperion Therapeutics, Inc.4$70
Sanofi-aventis U.S. LLC3$67
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$59
Antares Pharma, Inc.2$59
Biohaven Pharmaceuticals, Inc.2$56
Biohaven Pharmaceutical Holding Company Ltd.2$49
Tolmar, Inc.3$45
Collegium Pharmaceutical, Inc.2$41
Lucid Diagnostics Inc.2$39
Endo Pharmaceuticals Inc.2$37
Kowa Pharmaceuticals America, Inc.2$32
Mylan Specialty L.p.2$29
Phathom Pharmaceuticals, Inc.2$29
Kyowa Kirin, Inc.1$29
Acella Pharmaceuticals, LLC2$28
Biocryst US Sales Co., LLC1$28
Amarin Pharma, Inc.2$26
Xeris Pharmaceuticals, Inc.1$23
Boston Scientific1$22
Insmed, Inc.1$21
Avanir Pharmaceuticals, Inc.1$21
Bayer1$20
Seqirus USA Inc1$19
Eisai Inc.1$18
Biogen1$18
Genentech USA, Inc.2$17
Jazz Pharmaceuticals Inc.1$17
Daiichi Sankyo Inc.1$16
Halozyme Inc1$16
Almatica Pharma LLC1$15
Medtronic1$14

How this compares

$11,407 in reported general payments places this provider in the 95th percentile of 181 primary care providers in Massachusetts.

See all primary care providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$49,849
Medicare patients
325
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other primary care in Newburyport

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →